RecruitingPhase 3NCT06936215

Safety and Efficacy of Baricitinib on Skin Tightening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate

Studying Diffuse cutaneous systemic sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Principal Investigator
Dr MD. Fahad Hossain, MBBS, MD
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Intervention
tab baricitinib 4 mg daily(drug)
Enrollment
24 enrolled
Eligibility
18 years · All sexes
Timeline
20242025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06936215 on ClinicalTrials.gov

Other trials for Diffuse cutaneous systemic sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Diffuse cutaneous systemic sclerosis

← Back to all trials